Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Becoactin
- Development stage
- Unknown
- Lead developer
- Meyer Organics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Becoactin is an over-the-counter (OTC) appetite stimulant and nutritional supplement developed by Meyer Organics. It is formulated as a combination of cyproheptadine hydrochloride—a first-generation antihistamine with potent antiserotonergic and anticholinergic properties—and a blend of B-complex vitamins (including thiamine, riboflavin, pyridoxine, nicotinamide, and cyanocobalamin), amino acids (glycine), and essential minerals (iron and zinc). Becoactin is primarily indicated to stimulate appetite, promote healthy weight gain, and regularize metabolic activity in individuals experiencing poor appetite, eating disorders, or weight loss due to illness or stress.
- Brand names
- Becoactin
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on Becoactin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Becoactin.